CRNX Stock Summary and Trading Ideas (Crinetics Pharmaceuticals | NASDAQ:CRNX)

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Crinetics Pharmaceuticals trades on the NASDAQ stock market under the symbol CRNX.

As of June 30, 2026, CRNX stock price climbed to $37.41 with 260,123 million shares trading.

CRNX has a beta of 0.90, meaning it tends to be less sensitive to market movements. CRNX has a correlation of 0.04 to the broad based SPY ETF.

CRNX has a market cap of $3.94 billion. This is considered a Mid Cap stock.

Last quarter Crinetics Pharmaceuticals reported $10 million in Revenue and -$1.23 earnings per share. This beat revenue expectation by $2 million and met earnings estimates .

In the last 3 years, CRNX traded as high as $62.53 and as low as $15.76.

The top ETF exchange traded funds that CRNX belongs to (by Net Assets): VTI, IWM, VB, VBK, VXF.

CRNX has outperformed the market in the last year with a price return of +24.9% while the SPY ETF gained +22.7%. However, in the short term, CRNX had mixed performance relative to the market. It has underperformed in the last 3 months, returning +11.1% vs +18.1% return in SPY. But in the last 2 weeks, CRNX shares have fared better than the market returning +6.5% compared to SPY -0.8%.

CRNX support price is $35.80 and resistance is $38.08 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRNX shares will trade within this expected range on the day.